What this study can and cannot tell you

The creatinine verification supported one specific claim: on this analyzer, with these operators, this FDA-cleared unmodified method's precision, bias, reportable range, and reference interval are adequate for this laboratory's intended use. It did not reproduce the manufacturer's full FDA submission, and CMS guidance is explicit that verification is not meant to. It also did not establish clinical validity, meaning it said nothing about how a given creatinine result relates to a diagnosis of kidney injury; that is a separate question from whether the method measures creatinine concentration accurately.

What the study depends on locally: the director's predefined allowable-bias goal, the specific reference material and patient sample set used, and the laboratory's document-retention practice are all local-policy choices, not universal numbers. A different laboratory, a different analyte, or a different director could set different criteria and still be doing the work correctly, as long as the criteria were fixed before the data were reviewed.

What remains a boundary condition rather than a fixed fact: the LDT regulatory landscape changed in 2025 and general FDA enforcement discretion currently applies to most LDTs, subject to CLIA and state law, but that posture can shift again. A laboratory planning a validation for a noncleared method should re-check current FDA, CMS, and accreditor requirements rather than treat the FDA/CLIA enforcement posture described above as fixed.

A validation or verification study is only as good as the criteria it was checked against, so write the acceptance criterion down before looking at the first data point, every time.